Echnology Grant No. UNKP-19-3-IV (JC Sagi); by the National Analysis, Development and Innovation Workplace (NKFIH) Grants No. PD109200 (F.S.), PD134449 (A.G.) and K115861 (D.J.E.), by the Hungarian Paediatric Oncology Network (07/MGYH-MGYGYT/2018), and by the J os Bolyai Research Scholarship with the Hungarian Academy of Sciences (A.G.). The NOPHO study was supported by the Swedish Childhood Cancer Fund (KP2017-0010, TJ2020-0082, TJ2019-0031), by the Danish Childhood Cancer Fund and by the Danish Cancer Society (R150-A10181). The funders had no function in study design and style, information collection and evaluation, selection to publish, or preparation of the manuscript. Institutional Overview Board Statement: The study was conducted according to the principles expressed inside the Declaration of Helsinki for all nations. Written informed consent was requested from all sufferers or the parents or guardians of the minors involved inside the study. The study was authorized by the ethical committees in the participating countries. The study was authorized by the ethical committees inside the participating nations. These are: Ethics Committee of your Medical University of Vienna on three August 2010 (No. 641/2010) (Austrian sufferers); Ethics Committee of University Hospital Motol (approval file number NV15-30626A, authorized in August 2014) (Czech individuals); Ethics Committee on the Hungarian Medical Investigation Council (approval file quantity 12988-52-1018/-EKU, Date: 29 September 2003, 23310/2011/EKU, Date: 19 January 2012, ad. 60106-1/2015/EKU, Date: 21 December 2015) (Hungarian sufferers). The database containing phenotype data was approved by the regional ethical assessment board of your Capital Region of Denmark (H-2-2010-022), the Danish Data Protection Authorities (j.nr.: 2012-58-0004), and by relevant regulatory authorities in all participating countries. Genotype information had been stored in the Technical University of Denmark’s server Computerome (NOPHO individuals). Informed Consent Statement: All individuals or legal guardians on the sufferers supplied written informed consent in accordance with the Helsinki Declaration. The written informed consent was obtained in the participants or the legal guardians of participants beneath the age of 16 prior to they entered the study.Cancers 2021, 13,13 ofData Availability Statement: The datasets analyzed for the duration of the present study are accessible in the corresponding author on reasonable request. Acknowledgments: We are thankful to all the patients and handle subjects, nurses, physicians who took portion within this study. We thank to M ika S dornV gor the sample collection and preparation, for Anna Artner genotyping relapse samples, Shira Ben Neriah looking the scientific background of CNS toxicity. Conflicts of Interest: Andishe Attarbaschi: Honoraria: Jazz Pharmaceuticals, Amgen, Novartis, MSD; Consulting or Advisory Part: Jazz Pharmaceuticals, Amgen, Novartis, MSD, Gilead; eIF4 Inhibitor Formulation Travel, Accommodations, Expenditures: Jazz Pharmaceuticals. The other IL-15 Inhibitor Purity & Documentation authors declare no conflict of interest. The funders had no role in the design of your study; within the collection, analyses, or interpretation of information; within the writing from the manuscript, or inside the decision to publish the results.
virusesArticleTreatment Protocol for COVID-19 Determined by T2R PhenotypeMohamed A. Taha 1,2, , Christian A. Hall 1,3 , Colin J. Shortess 1 , Richard F. Rathbone 1 and Henry P. Barham 1,2Rhinology and Skull Base Analysis Group, Baton Rouge Basic Medical Center, 8585 Picardy Ave., Suite 210, Baton Rouge, LA 70809, USA.
